Gsk Plc Stock Cash Per Share
| G1SK34 Stock | BRL 42.80 1.00 2.28% |
GSK plc fundamentals help investors to digest information that contributes to GSK Plc's financial success or failures. It also enables traders to predict the movement of GSK Stock. The fundamental analysis module provides a way to measure GSK Plc's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GSK Plc stock.
GSK |
GSK plc Company Cash Per Share Analysis
GSK Plc's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, GSK plc has a Cash Per Share of 0.0 times. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers-General (which currently averages 0.0) industry. The cash per share for all Brazil stocks is 100.0% higher than that of the company.
Did you try this?
Run Technical Analysis Now
Technical AnalysisCheck basic technical indicators and analysis based on most latest market data |
| All Next | Launch Module |
GSK Fundamentals
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.51 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 484.56 B | |||
| Shares Outstanding | 4.09 B | |||
| Price To Book | 2.60 X | |||
| Price To Sales | 9.93 X | |||
| Revenue | 34.11 B | |||
| Gross Profit | 19.92 B | |||
| EBITDA | 8.6 B | |||
| Net Income | 4.38 B | |||
| Total Debt | 19.76 B | |||
| Book Value Per Share | 5.25 X | |||
| Cash Flow From Operations | 7.95 B | |||
| Earnings Per Share | 6.69 X | |||
| Price To Earnings To Growth | 0.45 X | |||
| Number Of Employees | 10 | |||
| Beta | 0.28 | |||
| Market Capitalization | 388.07 B | |||
| Total Asset | 79.1 B | |||
| Z Score | 11.4 | |||
| Annual Yield | 0.04 % | |||
| Net Asset | 79.1 B | |||
| Last Dividend Paid | 0.61 |
About GSK Plc Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GSK plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GSK Plc using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GSK plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in GSK Stock
GSK Plc financial ratios help investors to determine whether GSK Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GSK with respect to the benefits of owning GSK Plc security.